According to Webster's Dictionary [1] , a ''blip'' is a sudden minor shock or meaningless interruption. One of the earliest uses of this term in the human immunodeficiency virus (HIV) literature was by Wodarz and Nowak [2] in their conceptual HIV dynamics model that involved ''the occurrence of 'blips' of such [CXCR4-tropic HIV] mutants, which rapidly go extinct.'' Use of the term in the context of antiretroviral therapy (ART) became popular in the bygone era of limited ART options when the goal of therapy for many patients was maintenance of a stable CD4
1 T-cell count. In that era, a transient increase in plasma HIV-1 RNA load to levels #1000 copies/mL would have provoked little concern and been considered meaningless or inconsequential. There has since been dramatic improvement in the potency and tolerability of modern ART, making sustained levels of HIV-1 RNA ,50 copies/mL achievable for most patients. The sensitivity of qualitative and quantitative tools that can be used to interrogate subterranean virologic events is increasing, seemingly daily. Consequently, the magnitude of transient viremia that can be considered minor or inconsequential (ie, a blip) needs continual reexamination.
In the elegant retrospective observational cohort study by Grennan et al, published in this issue of the Journal [3] , viral blip was defined as a transient HIV-1 RNA increase to 50-999 copies/mL after attaining ,50 copies/mL during ART. The investigators achieved their objectives of (1) determining correlates of the transient HIV-1 RNA increases and (2) determining the impact on virologic rebound. Incidentally, their results also strengthen the need to narrow the definition of viral blip in clinical and research domains.
A strength of Grennan et al's study is the large number of HIV-12infected patients (N 5 4560) enrolled in the Canadian Observational Cohort through January 2009. From this cohort, Grennan et al identified a study population of 3550 patients with confirmed virologic suppression, defined as HIV-1 RNA ,50 copies/mL on 2 consecutive occasions at least 30 days apart. To avoid overestimating the incidence of transient viremia after suppression, $2 HIV-1 RNA increases to 50-999 copies/mL within a 30-day period were considered to be part of the same event. During a median observation period of 2.7 years, HIV-1 RNA was quantified a median of 11 times per patient, mirroring the practice in many clinical settings. Onequarter of the patients had .6 HIV-1 RNA tests per year, possibly reflecting additional testing that was done to evaluate measurements .50 copies/mL.
Grennan et al confirmed that transient viremia of 50-1000 copies/mL occurs commonly during ART and tends to cluster between 50 and 200 copies/mL. In addition, using an adjusted multivariable model, they revealed that patients monitored with the ultrasensitive Roche Amplicor HIV-1 Monitor (version 1.5) assay, a polymerase chain reaction (PCR) amplification-based assay, experienced lower rates of transient viremia compared with those monitored using the branched DNA (bDNA) assay (Chiron Corp). Techniques for HIV-1 RNA quantification can be divided broadly into those based on signal amplification with bDNA and those utilizing nucleic acid amplification with PCR. Although the results with different assays tend to have acceptable correlation at relatively high HIV-1 RNA levels, inter-and intra-assay variability may be significant around the lower quantification limits. In general, PCR amplification platforms are more likely to report low-level viremia in samples with undetectable HIV-1 RNA by bDNA [4] , making Grennan et al's finding intriguing. Because each plasma sample was not concurrently tested with the bDNA and PCR techniques, the impact of the assay platform could not be explored further. Nevertheless, the take-home message for clinicians is that there are differences between the performance characteristics of HIV-1 RNA quantification assays, underscoring the potential perils of interchanging assays in routine clinical practice [5] [6] [7] .
Some of the correlates of transient viremia identified by Grennan et al are consistent with evidence that the stage of HIV disease before ART initiation is an important predictor of transient viremia during ART [8] . Specifically, they found more frequent episodes of transient viremia among patients with higher HIV-1 RNA, lower CD4
1 T-cell count, or evidence of AIDS-defining illness before ART initiation. However, other correlates of transient viremia identified by the investigators challenge the existing literature. Notably, a correlation was detected with boosted protease inhibitor (PI)-based (but not unboosted PI-based) therapy. This finding must be interpreted cautiously, especially because detailed information was not provided on potential confounders such as specific PI used, adherence to ART, previous ART regimens or changes, and efficacy of non-PI drugs during each viremia episode. Therapy in which a PI is the only active agent has been associated with increased risk of low-level viremia, likely impacted by adherence and size of the HIV reservoir [9, 10] . The finding of Grennan et al is also contrasted by an earlier study that found equivalent incidence and prognosis of transient viremia during PI vs nonnucleoside reverse transcriptase inhibitor-based therapy [11] . One of the most important findings of Grennan et al is the correlation detected between HIV-1 RNA amplitude and subsequent virologic rebound. Defining virologic rebound as consecutive HIV-1 RNA $50 copies/mL measured at least 30 days apart (or any measurement .1000 copies/mL), virologic rebound was seen in 26% of patients; 14% of the rebounds were preceded by transient HIV-1 RNA of 50-999 copies/mL. Critically, only transient HIV-1 RNA $500 copies/mL correlated with rebound in multivariable analysis. As discussed by Grennan et al, other investigators have also found that for patients previously suppressed to ,50 copies/mL, transient HIV-1 RNA increases ,500 (or 400) copies/mL are not associated with subsequent virologic rebound, and some have found a gradation of rebound risk that increased with amplitude of viremia ,500 copies/mL. On the other hand, transient viremia $500 copies/mL has been associated with virologic rebound downstream, although not in all studies. These observations resound the need to narrow the definition of viral blips based on the premise that HIV-1 RNA increases of different amplitudes may be different phenomena, and those that are associated with subsequent rebound or resistance should not be considered blips.
Hypothetically, true blips primarily represent periodic viral release from latently infected cells (as opposed to replication) and are hence mechanistically similar to residual viremia, that is, ,50 copies/mL detected by single-copy assay [12] . Alternatively, true blips may be due to random HIV-1 RNA variation around a mean value of ,50 copies/mL [13] or laboratory assay artifacts [14] . In contrast, it appears as if other episodes of transient viremia (eg, those 500-999 copies/mL in the Grennan et al study) are not true blips because they may be associated with negative virologic consequences. Speculatively, such higheramplitude transient viremia may be associated with recent lapses in adherence or may reflect a short-lived burst of viral replication, extinguished spontaneously or aborted by host immune responses.
A case could be made for restricting use of the term ''blip'' to transient HIV-1 RNA #500 (or 400) copies/mL for now, while recognizing inherent imperfections. One potential benefit is that this would harmonize evaluation and interpretation of transient viremia in studies and in clinical care. In addition, it would likely motivate researchers to explore possible fundamental differences in the biology of transient viremia of different amplitudes. In these efforts, transient low-level viremia must not be confused with persistent low-level viremia. Unlike transient viremia, persistent viremia ,500 copies/mL has been associated with evolution of antiretroviral drug resistance, although clinical implications of emergent mutations are unclear [15] .
Which additional t's must be crossed in the quest to fully characterize the causes and consequences of transient viremia during ART? In addition to exploring the origin of transient viremia of different amplitudes, future studies should employ ultra-deep sequencing techniques to delineate the threshold HIV-1 RNA level, if any, above which HIV-1 sequence changes or development of resistance become a concern. Further, correlations between residual viremia and subsequent HIV-1 RNA rise above 50 copies/mL should be explored. The ongoing debate on possible associations between adherence and transient viremia of different amplitudes needs to be resolved. To optimize cross-study comparisons, the time interval that should elapse for consecutive episodes of viremia to be classified as separate events or the same episode should be demarcated more precisely. Finally, studies should explore how transient viremia (stratified by HIV-1 RNA amplitude) interacts with systemic immune activation and inflammation. Because HIV-1 RNA level correlates with the degree of immune activation during untreated HIV-1 infection [16] , it is essential to determine whether transient increases in viremia aggravate immune activation and/or inflammation during otherwise suppressive ART.
Meanwhile, the article by Grennan et al suggests that most patients with short-lived HIV-1 RNA increases to levels ,500 copies/mL from ,50 copies/mL can be reassured that such events are relatively common and unlikely to presage failure. In all cases, adherence must be emphasized and gaps in our understanding acknowledged.
